Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

62.70 +0.79 (+1.28%)
Streaming Delayed Price Updated: 11:16 AM EDT, Apr 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sarepta Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
Jim Cramer: This Industrial Stock Is Doing 'Very Well'; Here's His Take On Palantir
Jim Cramer likes Enbridge Inc. (NYSE: ENB), says Lazard, Inc. (NYSE: LAZ) is a good buy, and Advanced Drainage Systems, Inc. (NYSE: WMS) is an incredible infrastructure play. He also mentions Jacobs... 
Via Benzinga
Why Dyne Therapeutics, With A 108% Run This Year, Just Catapulted Again
Dyne Therapeutics is looking to take on Sarepta Therapeutics in DMD. 
Via Investor's Business Daily
12 Analysts Have This To Say About Sarepta Therapeutics
Via Benzinga
3 Biotech Stocks With the Potential to Make You an Overnight Millionaire
Don’t miss out on these stocks that could rock your portfolio with massive growth following FDA approvals and breakthrough treatments. 
Via InvestorPlace
Exposures Product Safety
Gene Therapy Pioneer Jerry R. Mendell, M.D., Named to Inaugural TIME100 Health List of the 100 Most Influential People in Global Health
From Sarepta Therapeutics, Inc.
Via Business Wire
What Analysts Are Saying About Sarepta Therapeutics Stock
Via Benzinga
Sarepta Therapeutics: Q4 Earnings Insights
Via Benzinga
Apple, Kellanova And 3 Stocks To Watch Heading Into Thursday
Via Benzinga
SRPT Stock Earnings: Sarepta Therapeutics Beats EPS, Beats Revenue for Q1 2024
SRPT stock results show that Sarepta Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Sarepta Therapeutics (SRPT) Q1 2024 Earnings Call Transcript
SRPT earnings call for the period ending March 31, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Sarepta Therapeutics Announces First Quarter 2024 Financial Results and Recent Corporate Developments
From Sarepta Therapeutics, Inc.
Via Business Wire
1 Top Growth Stock to Buy and Hold for 10 Years
This company's lineup might look very different in a decade, but the end result will be the same for investors. 
Via The Motley Fool
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
Sarepta Therapeutics Stock Shows Improved Technical Strength
The Relative Strength (RS) Rating for Sarepta Therapeutics stock headed into a new percentile Monday, as it got a lift from 70 to 73. 
Via Investor's Business Daily
Sarepta Therapeutics to Announce First Quarter 2024 Financial Results
From Sarepta Therapeutics, Inc.
Via Business Wire
Why Sarepta's First-Quarter Report Is Already Dead In The Water: Analyst
Sarepta stock has taken a beating this year, and it might not be over with the first-quarter report looming. 
Via Investor's Business Daily
2 Biotech Stocks to Buy Hand Over Fist in April
These drugmakers have made important moves over the past year. 
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
How Sleeper Biotech Solid Biosciences, With A 687% Gain, Is Making A Comeback
The company could follow Sarepta Therapeutics with a gene therapy for Duchenne muscular dystrophy. 
Via Investor's Business Daily
Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling?
The threat is still emerging, but it could be significant. 
Via The Motley Fool
This Gene Therapy Player Duchenne Data Is Impressive, Analyst Upgrades REGENXBIO
REGENXBIO's promising gene therapy advancements! RBC Capital Markets upgraded REGENXBIO (RGNX), citing impressive RGX-202 trial results in Duchenne patients. 
Via Benzinga
Got $1,000? Buy These Hot Growth Stocks Before They Take Off.
These stocks haven't been able to get much traction lately, even though they clearly deserve to now. 
Via The Motley Fool
Sarepta Therapeutics Stock Has 73% Upside, According to 1 Wall Street Analyst
The upcoming regulatory decision on its latest drug could be big. 
Via The Motley Fool
Sarepta Therapeutics to Present at Upcoming Investor Conferences
From Sarepta Therapeutics, Inc.
Via Business Wire
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
Sarepta Therapeutics Announces Call for Applications for the 7th Annual Route 79, The Duchenne Scholarship Program
From Sarepta Therapeutics, Inc.
Via Business Wire
Sarepta Therapeutics (SRPT) Q4 2023 Earnings Call Transcript
SRPT earnings call for the period ending December 31, 2023. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Recent Corporate Developments
From Sarepta Therapeutics, Inc.
Via Business Wire
Is It Too Late to Buy Sarepta Therapeutics Stock?
The company's hyperfocus on its core area could continue to be highly lucrative. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS